Navigation Links
It's a knock out: eIF4E-specific anti-sense oligonucleotides knock down cancer
Date:9/4/2007

A new study by Jeremy Graff and colleagues from Eli Lilly and Company has demonstrated the anti-cancer effect of a new therapeutic in a mouse model of human tumors and has spawned clinical trials to test the ability of this therapeutic to treat human cancers. As highlighted in the accompanying commentary by Celeste Simon and colleagues from the University of Pennsylvania, Philadelphia, if the therapeutic is as effective in clinical trials as it was in mice it will be useful for the treatment of a broad range of cancers.

The growth of many tumors is promoted by increased expression of the protein eIF4E, but no eIF4E-specific therapy has yet been developed. In this study, the intravenous administration of eIF4E-specific antisense oligonucleotides (ASOs) to mice bearing human tumors substantially inhibited tumor growth. Importantly, although these ASOs also decreased eIF4E expression in normal tissues, the function of the normal tissues analyzed was not compromised. The authors therefore suggest that tumor cells are more susceptible to decreased expression of eIF4E than normal cells, meaning that eIF4E-specific ASOs should not cause damage to normal tissues.

TITLE: Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity

AUTHOR CONTACT:

Jeremy R. Graff
Eli Lilly and Company, Indianapolis, Indiana, USA.
Phone: (317) 277-0220; Fax: (317) 277-3652; E-mail: graff_jeremy@lilly.com.

View the PDF of this article at: https://www.the-jci.org/article.php?id=32044

ACCOMPANYING COMMENTARY:

TITLE: Taking aim at translation for tumor therapy

AUTHOR CONTACT:

M. Celeste Simon
Abramson Family Cancer Institute, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.
Phone: (215) 746-5532; Fax: (215) 746-5511; E-mail: celeste2@mail.med.upenn.edu.

View the PDF of this article at: https://www.the-jci.org/article.php?id=33107


'/>"/>
Contact: Karen Honey
press_releases@the-jci.org
215-573-1850
Journal of Clinical Investigation
Source:Eurekalert

Related medicine news :

1. Alcohol a potential carcinogen: knocking on the door: pay heed!
2. Knock on the Head – No Small Thing After Al
3. Lethal Hospital Bug Tough to Knock Down, Statistics Reveal
4. The Tech Savvy Patient Knocks on the Doors of Telemedicine and Virtual Clinics
5. Knocking Out Survival Protein Could Aid Leukemia Treatment
6. Knocking Out Survival Protein Could Fight Leukemia
7. Chilean Presidents Cousin Successfully Tests Allergy Knockout Technique on Mice
8. Anti-Sense Drugs and Nanotechnology Offer New Hope In Cancer Fight
9. Fibroids unlikely to Turn Cancerous
10. Virus Level could Predict Cervical Cancer Risk
11. Cancer Doctors Okays Controversial Prostate Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2016)... ... ... wide variety of national pet product manufacturers, companies and brands will gather for one day ... from noon to 8 p.m. at New York City’s Roger Smith Hotel. The event is ... outdoor and safety pet products in today’s marketplace. , Petrend Event showcases the ...
(Date:5/6/2016)... ... May 06, 2016 , ... ... reduce fat areas around the body, is the most popular among body sculpting ... released make perfect sense to cosmetic surgeon Dr. Richard Buckley, medical director of ...
(Date:5/6/2016)... ... May 06, 2016 , ... From May 4 to 6, EarQ ... unique opportunity to learn more about Signia’s technology and the successful business and marketing ... our priority to see practices succeed in this highly competitive industry,” said Ed Keller, ...
(Date:5/6/2016)... ... 06, 2016 , ... The International Yoga Teacher Training schoo l ... island close to the town famous for its sunsets, Oia. This all inclusive yoga ... to have an amazing experience in Greece, we just can’t stay away” says Co-Founder ...
(Date:5/6/2016)... ... ... and Overseer at The House of Yahweh, has written a new article this week meant ... to stop cancer. Yisrayl says there are too many suffering and dying from the disease ... will pay close attention and take action. The Pastor says that the root cause of ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... JERUSALEM , May 4, 2016 ... University of Jerusalem announced today that it had ... BioTheryX, Inc. , developer of novel protein degradation ... the development and commercialization of drug candidates representing first-in-class ... the license were not disclosed. The novel ...
(Date:5/4/2016)... May 4, 2016 ... the  "Global Acute Ischemic Stroke Market and ... their offering.       (Logo: ... Acute Ischemic Stroke Market and Competitive Landscape ... Ischemic Stroke pipeline products, Acute Ischemic Stroke ...
(Date:5/3/2016)... 2016 Global Insulin Needles ... 09 key companies and supported with 272 tables ... study on the current state of the Insulin ... industry including definitions, classifications, applications and industry chain ... for the international market including development history, competitive ...
Breaking Medicine Technology: